← Eichor
Study identifier: NCT07039097 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on the Natural Pregnancy Outcomes in Patients With Non-recurrent Spontaneous Abortion

Condition: Infertility and Miscarriage  ·  Sponsor: The Third Xiangya Hospital of Central South University

PhaseNA
Planned participants418
Who can joinFemale, 20 Years to 40 Years
Healthy volunteersNo

About this study

The study aims to compare the effects of transcervical resection of septa (TCRS) and expectant management on the natural pregnancy outcomes of patients with septate uterus without recurrent abortion, also covering the treatment of other infertility factors in infertile patients who aim at natural conception. The research attempts to answer whether TCRS can improve the live birth rate, pregnancy rate and pregnancy outcomes for septate uterus patients planning natural pregnancy, so as to provide evidence-based medical evidence for the selection of clinical treatment methods for such patients.

This description comes directly from the study's public registry record.

Talk to the study team

Dabao Xu  ·  13017386201  ·  forxudabao@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Third Xiangya Hospital of Central South UniversityChangsha, Hunan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07039097